See every side of every news story
Get Started
SubscribeLogin
Published • loading... • Updated

FDA accepts NDA for ET-600, desmopressin oral solution for pediatric AVP deficiency

Summary by contemporarypediatrics.com
The FDA accepted Eton Pharmaceuticals' NDA for ET-600 for pediatric arginine vasopressin deficiency, with a target action date in February of 2026.
DisclaimerThis story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.

1 Articles

contemporarypediatrics.comcontemporarypediatrics.com

FDA accepts NDA for ET-600, desmopressin oral solution for pediatric AVP deficiency

The FDA accepted Eton Pharmaceuticals' NDA for ET-600 for pediatric arginine vasopressin deficiency, with a target action date in February of 2026.

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • There is no tracked Bias information for the sources covering this story.

Factuality 

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

contemporarypediatrics.com broke the news in on Tuesday, July 8, 2025.
Sources are mostly out of (0)
Stories disproportionately reported by the Left or the Right

Similar News Topics

United States icon

United States

News
For You
SearchBlindspotLocal